In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study

Autor: Christof Rottenburger, Michael Hentschel, Markus Fürstner, Lisa McDougall, Danijela Kottoros, Felix Kaul, Rosalba Mansi, Melpomeni Fani, A. Hans Vija, Roger Schibli, Susanne Geistlich, Martin Behe, Emanuel R. Christ, Damian Wild

Publikováno v: EJNMMI Research, Vol 14, Iss 1, Pp 1-13 (2024)

Abstract Background A new generation of radiolabeled minigastrin analogs delivers low radiation doses to kidneys and are considered relatively stable due to less enzymatic degradation. Nevertheless, relatively low tumor radiation doses in patients in

Externí odkaz: https://doaj.org/article/b2acaa6880e14783bd5cb5fd43fcbc99

Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study

Autor: A. Hans Vija, Tilman T. Rau, Michal Cachovan, Emanuel Christ, Anne Schumann, Felix Kaul, Christof Rottenburger, Martin Béhé, Susanne Geistlich, Damian Wild, Guillaume Nicolas, Katharina Glatz, Lisa McDougall, Roger Schibli

Publikováno v: Rottenburger, Christof; Nicolas, Guillaume P; McDougall, Lisa; Kaul, Felix; Cachovan, Michal; Vija, A Hans; Schibli, Roger; Geistlich, Susanne; Schumann, Anne; Rau, Tilman; Glatz, Kathrin; Behe, Martin; Christ, Emanuel R; Wild, Damian (2020). Cholecystokinin-2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma-Results of the Lumed Phase 0a Study. Journal of nuclear medicine, 61(4), pp. 520-526. Society of Nuclear Medicine 10.2967/jnumed.119.233031

Treatment of patients with advanced medullary thyroid carcinoma (MTC) is still a challenge. For more than 2 decades it is known that cholecystokinine-2 receptor (CCK2R) is a promising target for the treatment of MTC with radiolabeled minigastrin anal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efa4f387e84aedbeccba023a05e3a1bc
https://doi.org/10.2967/jnumed.119.233031

SPECT Imaging of SST2-Expressing Tumors with 99mTc-Based Somatostatin Receptor Antagonists: The Role of Tetraamine, HYNIC, and Spacers

Autor: Renata Mikolajczak, Rosalba Mansi, Lisa McDougall, Luigi Del Pozzo, Raghuvir Haridas Gaonkar, Fabius Wiesmann, Sandra Zanger, Melpomeni Fani

Publikováno v: Pharmaceuticals, Vol 14, Iss 300, p 300 (2021)
Pharmaceuticals
Volume 14
Issue 4

[99mTc]Tc-HYNIC-TOC is the most widely used 99mTc-labeled somatostatin receptor (SST) agonist for the SPECT imaging of SST-expressing tumors, such as neuroendocrine tumors. Recently, radiolabeled SST antagonists have shown improved diagnostic efficac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b030d8363d59da15717a0ae9e9c818dc
https://www.mdpi.com/1424-8247/14/4/300

Cholecystokinin 2 Receptor Agonist

Autor: Christof, Rottenburger, Guillaume P, Nicolas, Lisa, McDougall, Felix, Kaul, Michal, Cachovan, A Hans, Vija, Roger, Schibli, Susanne, Geistlich, Anne, Schumann, Tilman, Rau, Katharina, Glatz, Martin, Behe, Emanuel R, Christ, Damian, Wild

Publikováno v: J Nucl Med

Treatment of patients with advanced medullary thyroid carcinoma (MTC) is still a challenge. For more than 2 decades, it has been known that the cholecystokinin 2 receptor is a promising target for the treatment of MTC with radiolabeled minigastrin an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5a1a5d57208cb2e0639c78498b539b04
https://pubmed.ncbi.nlm.nih.gov/31519804

SUN-334 Evaluation of the CCK-2 Receptor Agonist 177Lu-PP-F11N for PRRT of Medullary Thyroid Carcinoma: Results of a Phase 0 'Lumed' Study

Autor: Lisa McDougall, Damian Wild, Roger Schibli, Felix Kaul, Christof Rottenburger, Martin Béhé, Susanne Geistlich, Guillaume Nicolas, Michal Cachovan, Emanuel Christ

Publikováno v: Journal of the Endocrine Society

Introduction: Despite the introduction of new molecular targeted therapies, there is still an unmet need for an effective systemic therapy for advanced medullary thyroid carcinoma (MTC). As MTC expresses cholecystokinine-2 (CCK-2) receptors at a high

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::516aeb95b409a4865fb073942621dfdd
https://doi.org/10.1210/js.2019-sun-334